dsip jhu Johns Hopkins University Advanced Academic Programs JHU Disability Research Day -

It binds all five somatostatin receptors (sst1-5) with affinities comparable to somatostatin, but uniquely also activates the ghrelin receptor (GHSR-1a)

It is currently in Phase 3 clinical trials, with seven additional trials expected to complete during the current year

Scientific studies show that nasal drug delivery often provides more consistent and predictable absorption than oral routes, reducing variability among individuals

BPC-157 exerts long-lasting effects by modulating growth factors, gene expression, and angiogenesis pathways, even after it is no longer detectable in plasma. Jere et al., Current Medicinal Chemistry Whats the Half-Life of BPC-157